Patients with anemia due to IPSS-R defined very low-, low-, or intermediate-risk MDS-RS who require RBC transfusions and who are refractory, intolerant or ineligible to prior erythropoiesis-stimulating agents (ESA) treatment
Conditions
Brief summary
RBC-TI rate according to IWG 2018 modified criteria[1] from Week 1 through Week 24
Detailed description
RBC-TI rate according to IWG 2006 criteria from Week 1 through Week 24 and through Week 52, Median time to RBC-TI (Week 1 through Week 24 and through Week 52), Median duration of RBC-TI (Week 1 through Week 24 and through Week 52), Change in RBC units transfused over a fixed 16-weeks period (Week 9 through Week 24 and Week 37 through Week 52) compared to the 16-week period prior to screening, Proportion of subjects achieving mean Hb increase ≥ 1.0 g/dL over ≥ 8 weeks (Week 1 through Week 24 and through Week 52), Proportion of subjects achieving modified hematologic improvement - erythroids (mHI-E) per IWG 2006 criteria (Week 1 through Week 24 and through Week 52), Proportion of subjects achieving hematologic improvement - neutrophils (HI-N) per IWG 2006 criteria (Week 1 through Week 24 and through Week 52), Proportion of subjects achieving hematologic improvement - platelets (HI-P) per IWG 2006 criteria (Week 1 through Week 24 and through Week 52), Mean change in serum ferritin from Week 9 through 24 and Week 37 through Week 52 compared to baseline, Mean change in mean daily dose of ICT from Week 9 through 24 and Week 37 through Week 52 compared to baseline, Proportion of subjects with progression to AML, Overall survival (OS), Safety measures: type, frequency, severity of adverse events (AEs) and relationship to luspatercept, dose reductions and dose delays, Mean change in PRO (via EORTC QLQ-C30) and PerfO (via “Timed Up and Go test” [TUG]) from baseline (Week 1) to Week 52 and to End of Treatment (EOT)
Interventions
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RBC-TI rate according to IWG 2018 modified criteria[1] from Week 1 through Week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| RBC-TI rate according to IWG 2006 criteria from Week 1 through Week 24 and through Week 52, Median time to RBC-TI (Week 1 through Week 24 and through Week 52), Median duration of RBC-TI (Week 1 through Week 24 and through Week 52), Change in RBC units transfused over a fixed 16-weeks period (Week 9 through Week 24 and Week 37 through Week 52) compared to the 16-week period prior to screening, Proportion of subjects achieving mean Hb increase ≥ 1.0 g/dL over ≥ 8 weeks (Week 1 through Week 24 and through Week 52), Proportion of subjects achieving modified hematologic improvement - erythroids (mHI-E) per IWG 2006 criteria (Week 1 through Week 24 and through Week 52), Proportion of subjects achieving hematologic improvement - neutrophils (HI-N) per IWG 2006 criteria (Week 1 through Week 24 and through Week 52), Proportion of subjects achieving hematologic improvement - platelets (HI-P) per IWG 2006 criteria (Week 1 through Week 24 and through Week 52), Mean change in serum ferritin from We | — |
Countries
Austria, Germany, Spain